Alkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint
Go back to Alkermes' (ALKS) FORWARD-5 Pivotal Phase 3 Study of ALKS 5461 for Major Depressive Disorder Mets Primary Endpoint| ALKERMES (NASDAQ: ALKS) | Delayed: 24.27 -0.38 (1.54%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $24.65 | 52 Week High | $80.71 | |||
| Open | $24.39 | 52 Week Low | $27.14 | |||
| Day High | $24.60 | P/E | 186.69 | |||
| Day Low | $23.89 | EPS | $0.13 | |||
| Volume | 354,678 | |||||
